Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Lowered by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 261,934 shares of the company’s stock after selling 13,509 shares during the quarter. JPMorgan Chase & Co. owned 0.48% of Voyager Therapeutics worth $1,532,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of VYGR. China Universal Asset Management Co. Ltd. increased its stake in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth about $74,000. Hsbc Holdings PLC acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at about $128,000. Verition Fund Management LLC acquired a new stake in Voyager Therapeutics in the 3rd quarter valued at about $216,000. Finally, Empowered Funds LLC raised its stake in shares of Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after buying an additional 2,278 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on VYGR shares. Wedbush started coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective for the company. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price objective for the company. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $15.97.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $5.53 on Friday. The stock’s 50-day simple moving average is $5.82 and its 200 day simple moving average is $6.67. Voyager Therapeutics, Inc. has a 52-week low of $4.99 and a 52-week high of $10.66. The stock has a market capitalization of $302.10 million, a P/E ratio of 7.79 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. Equities research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.